Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
1 other identifier
interventional
48
1 country
1
Brief Summary
This study examines whether exposition to hyperbaric oxygen after a road-race simulation can help competitive cyclists recover and perform better the following day. Hyperbaric oxygen, which involves breathing oxygen inside a pressurized chamber, is used as a recovery method in elite and professional sport. Its effectiveness, however, remains controversial: despite this widespread use, there is a lack of solid scientific evidence that a single HBO session after strenuous endurance exercise actually improves recovery, or that clarifies how the amount of oxygen exposure influences any benefit. The study includes healthy male road cyclists between 18 and 40 years of age who compete at the national level in Belgium. After completing a fatiguing cycling session, each participant is randomly assigned to one of four groups receiving different levels of oxygen exposure during recovery. Two groups breathe oxygen under increased pressure inside a chamber at either 2.5 or 1.4 atmospheres absolute. A third group breathes oxygen at normal pressure. The fourth group receives a sham condition that reproduces the treatment setting without active oxygen exposure. The study is double-blind, meaning that neither the participants nor the researchers assessing the outcomes know which condition each participant receives. The main goal is to determine whether a single session of post-exercise HBO improves next-day endurance performance, and whether higher oxygen exposure produces greater effects. The researchers also collect blood samples and physiological measurements to better understand how the body recovers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 15, 2026
CompletedFirst Posted
Study publicly available on registry
June 22, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
June 22, 2026
June 1, 2026
1.5 years
June 15, 2026
June 15, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Next-day endurance performance : Percent decrement in time to exhaustion from baseline
Endurance performance measured by a cycling time-to-exhaustion test at 105% of the lactate threshold power, expressed as the percentage decrement in time to exhaustion relative to the baseline test. Performance is compared SHAM to the other oxygen-exposure groups.
Throughout the entire study, approximately during 18 months
Study Arms (4)
HBO 2.5 ATA
EXPERIMENTALPiO₂ = 2.5 (100 % O₂ x 2.5 ATA)
HBO 1.4 ATA
EXPERIMENTALPiO₂ = 1.4 (100 % O₂ x 1.4 ATA)
NBO 1.0 ATA
EXPERIMENTALPiO₂ = 1.0 (100 % O₂ x 1.0 ATA)
SHAM
SHAM COMPARATORPiO₂ = 0.21 (21 % O₂ x 1.0 ATA)
Interventions
1h intervention after a fatiguing exercise
Eligibility Criteria
You may qualify if:
- Road cyclists competing in Elite 2 (Elite without professional contract) or Under-23 (U23) categories or equivalent \[Participation in national-level Belgian competitions within the previous 12 months. No specific ranking, finishing position, or performance threshold is required.\]
- ≥ 2 consecutive years of cycling experience at regional or national level, with structured and periodized training
- Cycling-specific training volume ≥ 8 h a week over the preceding 10 weeks
- Measured VO₂max ≥ 60 ml/kg/min
You may not qualify if:
- Presence of significant cardiovascular, pulmonary, neurological, ENT, or metabolic disease, including but not limited to: Uncontrolled arterial hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg) ; Unstable heart disease or decompensated cardiomyopathy
- Contraindications to hyperbaric exposure, including: Untreated pneumothorax, History of spontaneous pneumothorax without medical clearance ; Pulmonary conditions associated with air trapping (e.g. emphysema or bullous lung disease), or abnormal thoracic imaging when indicated ; Recent thoracic surgery
- Neurological contraindications, including epilepsy, history of oxygen-induced seizures, or recent seizure activity, and any association with cannabis use
- Ear, sinus, or Eustachian tube disorders preventing adequate pressure equalization, including active infection or history of severe barotrauma
- Severe claustrophobia incompatible with chamber exposure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Université Catholique de Louvainlead
- Murdoch Universitycollaborator
Study Sites (1)
Institute of Neuroscience, Université catholique de Louvain
Louvain-la-Neuve, Brabant-Wallon, 1348, Belgium
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 15, 2026
First Posted
June 22, 2026
Study Start
July 1, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
June 22, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share